Elisabeth A. de Blieck
University of Rochester
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Elisabeth A. de Blieck.
Journal of Inherited Metabolic Disease | 2012
Jennifer Cialone; Heather R. Adams; Erika F. Augustine; Frederick Marshall; Jennifer M. Kwon; Nicole Newhouse; Amy Vierhile; Erika Levy; Leon S. Dure; Katherine Rose; Denia Ramirez-Montealegre; Elisabeth A. de Blieck; Jonathan W. Mink
Juvenile neuronal ceroid lipofuscinosis (JNCL; CLN3 disease; Batten disease) is an autosomal recessive neurodegenerative disease of childhood. Symptoms typically present at school age with vision loss followed by progressive cognitive decline, motor dysfunction, seizures, and behavior problems. Studies on sex differences in JNCL have yielded mixed results, but parent anecdotes suggest that females experience a more precipitous disease course. Therefore, we sought to determine if sex-based differences exist in JNCL. We used data from the Unified Batten Disease Rating Scale (UBDRS), the Batten Disease Support and Research Association (BDSRA) database, and the PedsQL quality of life (QoL) survey to evaluate sex-based differences in functional independence and time from symptom onset to death. On average, females had JNCL symptom onset one year later and death one year earlier than did males. Despite a later age at onset, females had lower functional capability, earlier loss of independent function, and lower physical QoL. Future research in sex differences in JNCL may help to further understand the biological mechanisms underpinning the disease course and may point to targeted therapies.
JAMA Neurology | 2008
E. Ray Dorsey; Christopher A. Beck; Mary Adams; Gary Chadwick; Elisabeth A. de Blieck; Colleen McCallum; Leslie Briner; Lisa M. Deuel; Anthony Clarke; Rick Stewart; Ira Shoulson
BACKGROUND Communicating clinical trial results to research participants is seldom accomplished in a timely or an effective manner. OBJECTIVE To evaluate the effectiveness of a plan to communicate results in an industry-sponsored randomized controlled trial for Huntington disease. DESIGN, SETTING, AND PARTICIPANTS Postal survey to research participants at 28 of 41 research sites (including 217 of 316 participants) in Canada and the United States. INTERVENTION We communicated trial results by means of (1) a media release from the investigators within a day after a sponsor-issued press release; (2) a subsequent telephone call from the site staff to the participants; and (3) a conference call for research participants 2 weeks after the results were released. MAIN OUTCOME MEASURES Source and timing for learning study results and satisfaction with their communication. RESULTS Of the 217 study participants surveyed, 114 (52.5%) responded. Most (73.1%) first learned the study results from their sites telephone call, and 46.3% learned the results within 1 day of the sponsors press release. Participants reported high or complete satisfaction with the site telephone call (89.3%) and conference call (82.1%) but relatively low satisfaction with the sponsors press release (50.0%). Most respondents reported good understanding of the risks and benefits of the experimental treatment and the next steps for their participation. CONCLUSION Surveyed research participants learned of the clinical trial results soon after public release and highly valued the personalized and accurate communication efforts by the study investigators.
Journal of Child Neurology | 2007
Heather R. Adams; Jennifer M. Kwon; Frederick Marshall; Elisabeth A. de Blieck; David A. Pearce; Jonathan W. Mink
Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a progressive and fatal autosomal-recessive inherited lysosomal storage disorder of childhood. Core symptoms include vision loss, seizures, and mental and motor decline. This article presents data from 2 studies of neuropsychological function in juvenile neuronal ceroid lipofuscinosis. In the first cross-sectional pilot study, 15 children with genetic or clinicopathologic confirmation of juvenile neuronal ceroid lipofuscinosis completed a brief test of attention (mean age = 14.3 ± 2.9 years, range = 8.75-18.74 years; 7 males, 8 females). Average attention performances were significantly below age-expected normative data. A second longitudinal study was then initiated to study neuropsychological function in greater depth, including change in function over time. The authors have enrolled 18 children to date (mean age = 12.88 ± 3.59 years, range = 6.26-18.65; 11 males, 7 females). Of these, 5 children have completed a second (annual) re-evaluation. Results thus far indicate significant impairment in domains of auditory attention, memory, estimated verbal intellectual function, and verbal fluency. Neuropsychological impairment was significantly correlated with disease duration and with motor function as assessed by a disease-specific clinical neurologic rating scale. There was no significant difference between males and females in neuropsychological test performance. Neuropsychological function was worse among children with a positive seizure history. Juvenile neuronal ceroid lipofuscinosis—affected children exhibited significant and pervasive impairments on tests of auditory attention, verbal memory and repetition, verbal fluency, and an estimate of verbal intellectual ability. Preliminary follow-up data from an annual reassessment showed progressive declines in cognitive function, in particular on a task of working memory. Neuropsychological deficits are pervasive and progressive. Future research will focus on clarifying the relationship among disease duration, motor function, and neuropsychological performances, including the relative sensitivity of neuropsychological testing at different stages of motor impairment or disease duration.
Contemporary Clinical Trials | 2013
Elisabeth A. de Blieck; Erika F. Augustine; Frederick Marshall; Heather R. Adams; Jennifer Cialone; Leon S. Dure; Jennifer M. Kwon; Nicole Newhouse; Katherine Rose; Paul G. Rothberg; Amy Vierhile; Jonathan W. Mink
INTRODUCTION Juvenile neuronal ceroid lipofuscinosis (JNCL; Batten disease) is a rare, inherited, fatal lysosomal storage childhood disorder. True for many rare diseases, there are no treatments that impact the course of JNCL. The University of Rochester Batten Centers (URBC) mission is to find treatments to slow, halt, or prevent JNCL. OBJECTIVES Our initial objective was to develop clinical research infrastructure preparatory to clinical trials, establish a JNCL research cohort, construct a disease-specific clinical outcome measure, and validate a non-invasive diagnostic sampling method. The long-term objective is to design and implement JNCL clinical trials. METHODS The Unified Batten Disease Rating Scale (UBDRS) was developed. The Batten Disease Support and Research Association (BDSRA) referred participants; annual BDSRA meetings provided a mobile research setting for registry enrollment and UBDRS piloting. Neuropsychological examinations were performed, enabling external validation of the UBDRS. Buccal epithelial cell collection for genotyping was introduced. Telemedicine for remote UBDRS assessment was piloted. RESULTS The registry enrolled 198 families representing 237 children with NCL. The UBDRS was piloted, was validated and has been used to collect natural history data from 120 subjects. Funding and regulatory approval were obtained for a recently launched phase II clinical trial. Several additional lines of inquiry were reported. CONCLUSION The registry and BDSRA collaboration have enabled development of a clinical rating scale, natural history and neuropsychological studies, and genetic studies for disease confirmation. This work highlights an approach for preparatory natural history research and infrastructure development needed to facilitate efficient implementation of clinical trials in rare diseases.
Developmental Medicine & Child Neurology | 2010
Heather R. Adams; Christopher A. Beck; Erika Levy; Rachel Jordan; Jennifer M. Kwon; Frederick Marshall; Amy Vierhile; Erika F. Augustine; Elisabeth A. de Blieck; David A. Pearce; Jonathan W. Mink
Aim The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease‐causing deletion or compound heterozygous. The secondary aim was to cross‐validate the Child Behavior Checklist (CBCL) and the Unified Batten Disease Rating Scale (UBDRS), a disease‐specific JNCL rating scale.
Developmental Medicine & Child Neurology | 2006
Heather R. Adams; Elisabeth A. de Blieck; Jonathan W. Mink; Frederick Marshall; Jennifer M. Kwon; Leon S. Dure; Paul G. Rothberg; Denia Ramirez-Montealegre; David A. Pearce
We obtained information about the behavioral, psychiatric, and functional status of 26 children (13 males, 13 females) with juvenile neuronal ceroid lipofuscinosis (JNCL; mean age 12y 3mo [SD 3y 4mo]; range 6y 9mo to 18y 8mo). Twenty‐five children had visual impairment and 18 were known to have a positive seizure history before enrollment. Parents completed the Child Behavior Checklist, Scales of Independent Behavior ‐Revised, and a structured interview to assess obsessive‐compulsive symptoms. Participants exhibited a broad range of behavioral and psychiatric problems, rated as occurring frequently and/or as severe in more than half of the sample. Males and females did not differ with regard to the number of behavioral and psychiatric problems. Children were also limited in their ability to perform activities of daily living, including self‐care, hygiene, socialization, and other age‐appropriate tasks. Results provide a quantitative baseline for behavioral and psychiatric problems and functional level in JNCL, against which further decline can be measured. Longitudinal assessment of behavioral and psychiatric symptoms and functional abilities is continuing and will provide much‐needed data on the natural history of JNCL.
Journal of Inherited Metabolic Disease | 2011
Jennifer Cialone; Erika F. Augustine; Nicole Newhouse; Heather R. Adams; Amy Vierhile; Frederick Marshall; Elisabeth A. de Blieck; Jennifer M. Kwon; Paul G. Rothberg; Jonathan W. Mink
Juvenile neuronal ceroid lipofuscinosis (JNCL; CLN3 disease; Batten disease) is an autosomal recessive neurodegenerative disease of childhood that typically presents at school age with vision loss followed by progressive cognitive decline, motor dysfunction, seizures, and behavior problems. No therapy has been shown to slow the progression of disease in JNCL patients, and all current treatments are symptomatic. Flupirtine has been shown in vitro to reduce apoptosis in CLN3 lymphocytes. Based on that preclinical study, several children with JNCL were given flupirtine by their parents. The purpose of this study was to determine if there was evidence of attenuated disease progression in any JNCL symptom domain. We administered a survey to parents of JNCL children to qualitatively assess flupirtine efficacy. We used the Unified Batten Disease Rating Scale (UBDRS) to determine specific aspects of disease progression and investigated three age-related factors: loss of independent ambulation, loss of intelligible speech, and loss of ability to perform independent activities of daily living. The median scores for the UBDRS physical, behavior, and capability subscales were determined in flupirtine-exposed subjects and compared to age-, sex-, and genotype-matched subjects who had never taken flupirtine. Twenty-one percent of survey responders reported administering flupirtine to their JNCL child, and 56% of these families perceived beneficial changes that they attributed to flupirtine. However, our quantitative, prospectively obtained data did not show any change in JNCL disease progression that could be attributed to flupirtine. This study highlights the need for prospective experimental therapeutic research.
Molecular Genetics and Metabolism | 2013
Jonathan W. Mink; Erika F. Augustine; Frederick Marshall; Heather R. Adams; Jennifer M. Kwon; Amy Vierhile; Elisabeth A. de Blieck
Molecular Genetics and Metabolism | 2013
Elisabeth A. de Blieck; Heather R. Adams; Erika F. Augustine; Jennifer Cialone; Leon S. Dure; Jennifer M. Kwon; Frederick Marshall; Nicole Newhouse; Katherine Rose; Paul G. Rothberg; Amy Vierhile; Jonathan W. Mink
Journal of Inherited Metabolic Disease | 2012
Jennifer Cialone; Heather R. Adams; Erika F. Augustine; Frederick Marshall; Jennifer M. Kwon; Nicole Newhouse; Amy Vierhile; Erika Levy; Leon S. Dure; Katherine Rose; Denia Ramirez-Montealegre; Elisabeth A. de Blieck; Jonathan W. Mink